Early Disease Activity or Clinical Response as Predictors of Long‐Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis

OBJECTIVE: Early identification of patients unlikely to achieve good long‐term disease control with anti–tumor necrosis factor therapy in axial spondyloarthritis (SpA) and psoriatic arthritis (PsA) is important for physicians following treat‐to‐target recommendations. Here we assess associations bet...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Heijde, D., Deodhar, A., Fleischmann, R., Mease, P. J., Rudwaleit, M., Nurminen, T., Davies, O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Spondyloarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518306/
https://www.ncbi.nlm.nih.gov/pubmed/27696727
http://dx.doi.org/10.1002/acr.23092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518306/
https://www.ncbi.nlm.nih.gov/pubmed/27696727
http://dx.doi.org/10.1002/acr.23092

Ejemplares similares